Drug intelligence / Profile preview

VTK-125

Development stage
Preclinical
Lead developer
Vitarka Therapeutics
Modality
PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01

Overview

VTK-125 is a pan-RAS protein degrader being developed by Vitarka Therapeutics for the treatment of Glioblastoma Multiforme (GBM). The drug is specifically engineered to be blood-brain barrier (BBB) permeable, allowing for effective delivery to the central nervous system (CNS). As a pan-RAS degrader, VTK-125 is designed to target and eliminate multiple isoforms of the RAS protein family, including KRAS, HRAS, and NRAS, which are key drivers in oncogenic signaling and tumor progression in glioblastoma. The program is currently in the preclinical stage of development.

Other names
Pan-RAS Degrader
02

Targets

HRAS (H-Ras protein)KRAS (Kirsten rat sarcoma viral oncogene homolog)NRAS (Neuroblastoma RAS viral oncogene homolog)

Beyond the preview

Go deeper on VTK-125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTK-125.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call